Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
Amphista and Merck will collaborate to leverage Amphista's proprietary Eclipsys TPD platform and generate novel protein degrading therapeutics in oncology and immunologyCollaboration includes
United Kingdom Doug Haslam Nicola Thompson Eli Lilly Berry Company Public Relations Advent Life Sciences
Source: finanznachrichten.de